vs
Apellis Pharmaceuticals, Inc.（APLS）与WW INTERNATIONAL, INC.（WW）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是WW INTERNATIONAL, INC.的1.1倍（$199.9M vs $184.3M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -30.5%，领先1.0%），WW INTERNATIONAL, INC.同比增速更快（-4.5% vs -5.9%），WW INTERNATIONAL, INC.自由现金流更多（$8.4M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -7.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
WW国际前身为慧俪轻体国际，是一家总部位于美国的全球性企业，主营减重与体重管理、健身及心态调整相关服务，核心产品为慧俪轻体综合减重饮食方案。公司由纽约皇后区的家庭主妇珍·妮德奇于1963年创立，截至2019年，其服务包含手机应用及网站线上方案、线上或电话指导、线下见面会三种模式。
APLS vs WW — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $184.3M |
| 净利润 | $-59.0M | $-56.3M |
| 毛利率 | — | 72.2% |
| 营业利润率 | -25.6% | 5.8% |
| 净利率 | -29.5% | -30.5% |
| 营收同比 | -5.9% | -4.5% |
| 净利润同比 | -62.2% | -21.8% |
| 每股收益（稀释后） | $-0.40 | $-5.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $184.3M | ||
| Q2 25 | $178.5M | — | ||
| Q1 25 | $166.8M | $186.6M | ||
| Q4 24 | $212.5M | $184.4M | ||
| Q3 24 | $196.8M | $192.9M | ||
| Q2 24 | $199.7M | $202.1M | ||
| Q1 24 | $172.3M | $206.5M |
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-56.3M | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | $-72.6M | ||
| Q4 24 | $-36.4M | $25.1M | ||
| Q3 24 | $-57.4M | $-46.2M | ||
| Q2 24 | $-37.7M | $23.3M | ||
| Q1 24 | $-66.4M | $-347.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | — | 69.7% | ||
| Q3 24 | — | 67.1% | ||
| Q2 24 | — | 67.9% | ||
| Q1 24 | — | 66.7% |
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 5.8% | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | -10.8% | ||
| Q4 24 | -12.3% | 19.6% | ||
| Q3 24 | -24.0% | -20.2% | ||
| Q2 24 | -14.7% | 17.8% | ||
| Q1 24 | -36.0% | -130.4% |
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -30.5% | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | -38.9% | ||
| Q4 24 | -17.1% | 13.6% | ||
| Q3 24 | -29.2% | -23.9% | ||
| Q2 24 | -18.9% | 11.5% | ||
| Q1 24 | -38.5% | -168.4% |
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $-5.63 | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | $-0.91 | ||
| Q4 24 | $-0.30 | $0.34 | ||
| Q3 24 | $-0.46 | $-0.58 | ||
| Q2 24 | $-0.30 | $0.29 | ||
| Q1 24 | $-0.54 | $-4.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $170.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $323.0M |
| 总资产 | $1.1B | $968.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $170.1M | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | $236.3M | ||
| Q4 24 | $411.3M | $53.0M | ||
| Q3 24 | $396.9M | $57.2M | ||
| Q2 24 | $360.1M | $42.7M | ||
| Q1 24 | $325.9M | $66.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | $93.1M | $1.4B |
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $323.0M | ||
| Q2 25 | $156.3M | — | ||
| Q1 25 | $164.2M | $-1.2B | ||
| Q4 24 | $228.5M | $-1.1B | ||
| Q3 24 | $237.1M | $-1.1B | ||
| Q2 24 | $264.3M | $-1.1B | ||
| Q1 24 | $266.7M | $-1.1B |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $968.8M | ||
| Q2 25 | $821.4M | — | ||
| Q1 25 | $807.3M | $696.9M | ||
| Q4 24 | $885.1M | $550.3M | ||
| Q3 24 | $901.9M | $562.4M | ||
| Q2 24 | $904.5M | $614.3M | ||
| Q1 24 | $831.9M | $654.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $8.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $8.4M |
| 自由现金流率自由现金流/营收 | -7.1% | 4.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $44.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $8.4M | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | $15.0M | ||
| Q4 24 | $19.4M | $4.6M | ||
| Q3 24 | $34.1M | $16.5M | ||
| Q2 24 | $-8.3M | $-1.9M | ||
| Q1 24 | $-133.0M | $-36.0M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $8.4M | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | $15.0M | ||
| Q4 24 | $19.3M | $4.5M | ||
| Q3 24 | — | $16.4M | ||
| Q2 24 | $-8.4M | $-2.2M | ||
| Q1 24 | $-133.3M | $-36.5M |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 4.6% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | 8.0% | ||
| Q4 24 | 9.1% | 2.4% | ||
| Q3 24 | — | 8.5% | ||
| Q2 24 | -4.2% | -1.1% | ||
| Q1 24 | -77.3% | -17.7% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.08× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
WW
暂无分部数据
